The FDA published a Federal Register notice today confirming that its Pharmacy Compounding Advisory Committee (PCAC) will meet July 23-24, 2026, to vote on whether seven specific peptides should be moved from Category 2 to Category 1 on the 503A bulks list. If the vote passes, compounding pharmacies across the United States would be able to prepare these peptides with individual prescriptions for the first time since the 2023 restrictions took effect.
The seven peptides named in the notice are BPC-157, TB-500 (Thymosin Beta-4 fragment), KPV, MOTS-c, Emideltide (DSIP), Epitalon, and Semax. A second PCAC meeting, scheduled before the end of February 2027, will review five additional peptides.
HHS Secretary Robert F. Kennedy Jr. framed the announcement as a public health measure, stating that the action begins restoring regulated access and will shift demand away from unregulated sources.
This is the most significant regulatory development for peptide access since the FDA placed dozens of peptides on the Category 2 restricted list in late 2023. Here is what the announcement actually means, what it does not mean, and what happens next.
Table of Contents
- The 7 Peptides on the July Agenda
- What Category 1 vs Category 2 Actually Means
- Timeline: From Announcement to Your Pharmacy
- The 5 Peptides Coming in 2027
- What About the Peptides Not on the List?
- Reclassification Is Not FDA Approval
- The Criticism
- What This Means for Current Peptide Users
- Frequently Asked Questions
The 7 Peptides on the July Agenda
These are the seven peptides the PCAC will evaluate at its July 23-24 meeting. Each has an existing body of published research and an established history of use in compounding pharmacy settings before the 2023 restrictions.
| Peptide | Primary Research Focus | PubMed Studies | PeptideWiki Guide |
|---|---|---|---|
| BPC-157 | Tissue repair, gut healing, tendon and ligament recovery | 100+ | Dosage Guide |
| TB-500 | Wound healing, inflammation, cardiac tissue repair | 70+ | Dosage Guide |
| KPV | Anti-inflammatory, gut mucosal health, skin conditions | 30+ | Dosage Guide |
| MOTS-c | Metabolic regulation, exercise mimetic, insulin sensitivity | 50+ | Dosage Guide |
| Emideltide (DSIP) | Sleep regulation, stress adaptation, circadian rhythm | 40+ | Dosage Guide |
| Epitalon | Telomerase activation, circadian regulation, anti-aging research | 30+ | Dosage Guide |
| Semax | Neuroprotection, cognitive function, BDNF upregulation | 80+ | Dosage Guide |
BPC-157 is the most widely known peptide on this list. Body Protection Compound-157 is a 15-amino-acid synthetic peptide derived from a protective protein found in human gastric juice. The published literature spans tissue repair across tendons, ligaments, muscle, gut lining, and bone. It is the peptide most frequently cited in the compounding pharmacy debate because of its broad research base and established use history. Full BPC-157 profile.
TB-500 is a synthetic fragment of Thymosin Beta-4, a naturally occurring 43-amino-acid protein involved in cell migration, blood vessel formation, and wound healing. Research has focused on cardiac tissue repair after injury, inflammation reduction, and accelerated recovery from soft tissue damage. Full TB-500 profile.
KPV is a tripeptide fragment of alpha-melanocyte stimulating hormone (alpha-MSH, a signaling molecule produced by the pituitary gland). It retains the parent hormone's anti-inflammatory activity without its skin-darkening effects. Research centers on inflammatory bowel conditions and skin inflammation, where it modulates NF-kB signaling, a key pathway in the inflammatory response. Full KPV profile.
MOTS-c is a mitochondrial-derived peptide, meaning it is encoded in mitochondrial DNA rather than nuclear DNA. It functions as an exercise mimetic, activating AMPK (a cellular energy sensor that triggers metabolic adaptation) and improving insulin sensitivity. Published research links MOTS-c to metabolic regulation, physical performance, and age-related metabolic decline. Full MOTS-c profile.
Emideltide, better known as DSIP (Delta Sleep-Inducing Peptide), is a nine-amino-acid peptide originally isolated from rabbit brain tissue in 1977. Despite its name, its mechanism involves broad stress adaptation and circadian rhythm modulation rather than direct sedation. Research applications include sleep architecture, stress response, and neuroendocrine regulation. Full DSIP profile.
Epitalon is a four-amino-acid synthetic peptide (Ala-Glu-Asp-Gly) based on the natural peptide epithalamin, produced by the pineal gland. Its primary mechanism involves telomerase activation, the enzyme responsible for maintaining telomere length at chromosome ends. Research from the St. Petersburg Institute of Bioregulation and Gerontology has focused on aging biomarkers and circadian regulation. Full Epitalon profile.
Semax is a synthetic heptapeptide based on a fragment of adrenocorticotropic hormone (ACTH, a pituitary hormone involved in the stress response). Developed at the Institute of Molecular Genetics in Moscow, it has been approved as a pharmaceutical in Russia since 1994 for cognitive and neurological applications. The research base covers neuroprotection, BDNF upregulation (brain-derived neurotrophic factor, a protein essential for neuron growth and survival), and cognitive enhancement. Full Semax profile.
What Category 1 vs Category 2 Actually Means
The FDA maintains a "bulks list" that determines which substances compounding pharmacies can use. Understanding the two categories is essential to understanding what this vote actually changes.
Category 1 substances are eligible for compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act. This means a licensed compounding pharmacy can prepare the substance into a finished product (typically an injectable, capsule, or cream) based on an individual prescription from a licensed practitioner. Category 1 is the standard pathway for most compounded medications.
Category 2 substances are restricted. They cannot be compounded until the FDA completes a formal review process, which includes an evaluation by the PCAC. A substance on the Category 2 list is effectively unavailable through legal compounding channels.
503A vs 503B. Section 503A covers traditional compounding pharmacies that fill individual prescriptions. Section 503B covers outsourcing facilities that can produce larger batches without individual prescriptions. The July vote applies to 503A compounding. 503B access is a separate regulatory question with its own review process.
Before 2023, most peptides existed in a regulatory gray area. They were not explicitly on the Category 1 list, but compounding pharmacies prepared them under the general 503A framework. In late 2023, the FDA placed dozens of peptides on the Category 2 restricted list, effectively halting legal compounding access overnight. The July PCAC meeting is the first formal opportunity to reverse specific restrictions.
Timeline: From Announcement to Your Pharmacy
A favorable PCAC vote does not mean peptides appear on pharmacy shelves the next day. Here is the realistic path from today's announcement to actual availability.
Step 1: Public Comment Period (Now through mid-June 2026). The Federal Register notice opens a 60-day public comment window. Anyone, including researchers, practitioners, patients, and industry representatives, can submit comments to the FDA about the proposed reclassification. The PCAC will review these comments before the vote.
Step 2: PCAC Vote (July 23-24, 2026). The advisory committee meets and votes on each peptide individually. PCAC votes are advisory, meaning the FDA is not legally bound by the outcome, but the agency follows committee recommendations in the vast majority of cases.
Step 3: FDA Final Rule (Late 2026, estimated). If the PCAC recommends reclassification, the FDA must publish a final rule moving the peptides from Category 2 to Category 1. This involves internal review and typically takes several months after an advisory committee vote.
Step 4: 503A Compounding Begins (Late 2026 to Q1 2027, estimated). Once the final rule is published, compounding pharmacies can legally source bulk peptide material and begin preparing finished products with valid prescriptions. Pharmacies will need to establish supply chains, quality testing, and practitioner relationships, which adds additional lead time.
The realistic window for patient access is late 2026 at the earliest, with Q1 2027 more likely for broad availability. Anyone claiming these peptides will be available immediately after the July vote is misrepresenting the regulatory process.
The 5 Peptides Coming in 2027
The Federal Register notice also confirms a second PCAC meeting before the end of February 2027 to evaluate five additional peptides. The specific five have not been named in the April 15 notice. The FDA will publish a separate Federal Register announcement with the meeting date and peptide list closer to the event.
Based on the original 14-peptide list from the February 2026 announcement and the seven selected for July, the remaining candidates likely include some combination of GHK-Cu, Thymosin Alpha-1, PT-141, Selank, and Dihexa. This is informed speculation based on the original announcement, not confirmed by the FDA.
The two-phase approach reflects the PCAC's capacity constraints. Reviewing the safety and compounding suitability data for each peptide requires preparation time, expert testimony, and deliberation. Splitting the review across two meetings allows more thorough evaluation.
What About the Peptides Not on the List?
The original Category 2 restricted list included significantly more than 14 peptides. Several popular compounds appear unlikely to be included in either review phase.
Growth hormone secretagogues (CJC-1295, Ipamorelin, GHRP-2, GHRP-6, Hexarelin) face the steepest path. These peptides stimulate growth hormone release and overlap with the pharmacology of FDA-approved GH products. The FDA has historically treated substances that replicate the effects of approved drugs with greater scrutiny under the compounding framework.
AOD-9604, a modified fragment of human growth hormone studied for fat metabolism, has limited published safety data relative to its popularity and shares the GH-adjacent regulatory concern.
Melanotan II triggers melanogenesis (skin darkening) and has well-documented off-target effects including nausea and changes in blood pressure. Its safety profile is the primary obstacle to reclassification.
These peptides remaining on Category 2 does not mean they are inherently dangerous. It means the FDA has not received or reviewed sufficient data to clear them for unsupervised compounding under 503A. Future PCAC meetings could address additional peptides if supporting data is submitted through the public comment process.
Reclassification Is Not FDA Approval
This distinction matters. Moving a peptide from Category 2 to Category 1 means compounding pharmacies can prepare it. It does not mean:
-
FDA-approved drug. Category 1 peptides have no FDA-approved labeling, no approved indications, and no requirement for clinical trials demonstrating efficacy. They are permitted for compounding, not endorsed as treatments.
-
Standardized manufacturing. Each compounding pharmacy sets its own quality controls, sourcing, and testing protocols. Quality will vary between pharmacies. Patients should look for pharmacies that provide certificates of analysis (third-party purity testing) for their compounded peptides.
-
Insurance coverage. Compounded medications are rarely covered by insurance. Patients should expect to pay out of pocket, similar to the current gray-market pricing structure but with the significant advantage of verified purity and physician oversight.
-
Over-the-counter availability. A prescription from a licensed practitioner is required. Category 1 compounding is not the same as retail sale.
The practical benefit of reclassification is not FDA endorsement. It is the transition from unregulated gray-market sourcing to regulated pharmacy preparation with quality controls, practitioner oversight, and legal accountability.
The Criticism
The announcement has drawn sharp criticism from parts of the medical and public health community.
Former FDA associate commissioner Dr. Peter Lurie, now president of the Center for Science in the Public Interest, has argued that expanding compounding access for peptides with limited clinical trial data creates patient safety risks. His concern centers on the gap between published research (mostly animal studies and small human trials) and the scale of clinical use that compounding access would enable.
Dr. Eric Topol, director of the Scripps Research Translational Institute, has questioned whether the evidence base supports the safety and efficacy claims made by peptide proponents. His position is that the standard for compounding access should require more robust human data than currently exists for most peptides on the list.
Supporters counter that the 2023 restrictions pushed an estimated hundreds of thousands of peptide users to unregulated sources with no quality controls, no physician oversight, and no adverse event reporting. From this perspective, regulated compounding access, even without full FDA approval, represents a net improvement in patient safety compared to the gray-market status quo.
PeptideWiki presents published research and does not take a policy position on the reclassification debate. The profiles and dosage guides linked throughout this article reflect the current state of published evidence for each peptide.
What This Means for Current Peptide Users
If you are currently sourcing peptides from research chemical vendors or overseas suppliers, the July vote could change your access model within the next 6-12 months. Here is what regulated compounding access would offer:
Verified purity. Compounding pharmacies that follow USP (United States Pharmacopeia) standards test raw materials and finished products. This eliminates the uncertainty around purity, contamination, and accurate dosing that characterizes gray-market products.
Physician oversight. A prescription requirement means a licensed practitioner reviews your health history, current medications, and specific protocol before you begin. This does not guarantee perfect outcomes, but it adds a layer of medical judgment that self-directed use lacks.
Legal clarity. Purchasing peptides prepared by a licensed 503A pharmacy with a valid prescription is unambiguously legal. The current gray-market model, where peptides are sold "for research purposes only," exists in a legal gray area that creates risk for both buyers and sellers.
Consistent dosing. Compounding pharmacies prepare peptides to specified concentrations using calibrated equipment. This reduces the variability in reconstitution, concentration, and dosing accuracy that occurs with self-preparation from lyophilized powder.
If you are already working with a physician or clinic that prescribes peptides, ask them about their plans for transitioning to 503A-compounded products once reclassification takes effect. If you are self-directing your peptide use, the reclassification creates an opportunity to bring a practitioner into the process.
For protocol details on the seven peptides under review, see the dosage guides linked in the table above.
Frequently Asked Questions
When will the PCAC vote happen?
The PCAC meeting is confirmed for July 23-24, 2026. The committee will evaluate and vote on each of the seven peptides individually during the two-day session.
Which 7 peptides are included in the July vote?
BPC-157, TB-500 (Thymosin Beta-4 fragment), KPV, MOTS-c, Emideltide (DSIP), Epitalon, and Semax. These were selected from the broader list of 14 peptides announced in February 2026.
Will BPC-157 be legal to buy after the vote?
Not immediately. If the PCAC recommends reclassification and the FDA publishes a final rule, BPC-157 would become available through licensed compounding pharmacies with a valid prescription. The realistic timeline for pharmacy availability is late 2026 to Q1 2027. It will not be available over the counter.
What is the difference between Category 1 and Category 2?
Category 1 substances can be compounded by licensed 503A pharmacies with an individual prescription. Category 2 substances are restricted and cannot be compounded until the FDA formally clears them through the PCAC review process. The July vote is the mechanism for moving peptides from Category 2 to Category 1.
Do I need a prescription for compounded peptides?
Yes. Under the 503A framework, compounding pharmacies prepare medications based on individual prescriptions from licensed practitioners. This is different from the current gray-market model where peptides are sold as research chemicals without prescriptions.
Will insurance cover compounded peptides?
Unlikely. Compounded medications are rarely covered by commercial insurance or Medicare. Most patients pay out of pocket for compounded prescriptions. Pricing will vary by pharmacy, peptide, and preparation format.
What about peptides not on the July list?
Five additional peptides will be reviewed at a second PCAC meeting before February 2027. The specific five have not been named yet. Growth hormone secretagogues (CJC-1295, Ipamorelin, GHRP-2, GHRP-6) and several other popular peptides are not included in either confirmed review phase and would require future PCAC meetings to be considered.
How can I submit a public comment to the FDA?
The Federal Register notice includes a docket number for public comments. Comments can be submitted through the Regulations.gov portal during the 60-day comment period (approximately through mid-June 2026). Comments from researchers, practitioners, and patients with firsthand experience are the most impactful submissions.
PeptideWiki provides educational information about research peptides. This content is not medical advice. Always consult with a qualified healthcare provider before beginning any peptide protocol. See our full disclaimer for details.
